您的购物车当前为空
IR415 选择性地与 HBx 相互作用 (Kd=2 nM) 并阻断 HBV 介导的 RNAi 抑制,逆转 HBx 蛋白对 Dicer 核糖核酸内切酶活性的抑制作用。IR415 具有抗 HBV 的活性。


为众多的药物研发团队赋能,
让新药发现更简单!
IR415 选择性地与 HBx 相互作用 (Kd=2 nM) 并阻断 HBV 介导的 RNAi 抑制,逆转 HBx 蛋白对 Dicer 核糖核酸内切酶活性的抑制作用。IR415 具有抗 HBV 的活性。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 170 | 现货 | |
| 5 mg | ¥ 387 | 现货 | |
| 10 mg | ¥ 690 | 现货 | |
| 25 mg | ¥ 1,390 | 现货 | |
| 50 mg | ¥ 2,390 | 现货 | |
| 100 mg | ¥ 3,400 | 现货 | |
| 200 mg | ¥ 4,730 | 现货 | |
| 1 mL x 10 mM (in DMSO) | ¥ 437 | 现货 |
| 产品描述 | IR415 selectively interacts with Hepatitis B virus X protein (HBx, Kd = 2 nM) and blocks HBV-mediated RNAi suppression, reverses the inhibitory effect of HBx protein on the activity of the dicer endoribonuclease. IR415 is a potent anti-HBV agent and inhibits HBV replication by blocking the HBx activity. |
| 靶点活性 | HBx:2 nM(Kd) |
| 体外活性 | IR415 (50-200 μM) has a dose-dependent inhibitory effect on HBx, with a minimal effective concentration of 50 μM in HepG2/GFP-shRNA line transfected with HBx.Hepatitis B virus X protein (HBx) as a suppressor of host defenses consisting of RNAi-based silencing of viral genes. |
| 分子量 | 296.34 |
| 分子式 | C13H14F2N4S |
| CAS No. | 452967-14-5 |
| Smiles | Fc1ccc(NC(=S)NCCCn2ccnc2)c(F)c1 |
| 密度 | 1.32 g/cm3 (Predicted) |
| 颜色 | White |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 125 mg/mL (421.81 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (13.5 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
对于不同动物的给药剂量换算,您也可以参考 更多